177 related articles for article (PubMed ID: 33386676)
1. Serum thrombospondin 2 is a novel predictor for the severity in the patients with NAFLD.
Kimura T; Tanaka N; Fujimori N; Yamazaki T; Katsuyama T; Iwashita Y; Pham J; Joshita S; Pydi SP; Umemura T
Liver Int; 2021 Mar; 41(3):505-514. PubMed ID: 33386676
[TBL] [Abstract][Full Text] [Related]
2. Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.
Kozumi K; Kodama T; Murai H; Sakane S; Govaere O; Cockell S; Motooka D; Kakita N; Yamada Y; Kondo Y; Tahata Y; Yamada R; Hikita H; Sakamori R; Kamada Y; Daly AK; Anstee QM; Tatsumi T; Morii E; Takehara T
Hepatology; 2021 Nov; 74(5):2452-2466. PubMed ID: 34105780
[TBL] [Abstract][Full Text] [Related]
3. Circulating thrombospondin 2 levels reflect fibrosis severity and disease activity in HCV-infected patients.
Iwadare T; Kimura T; Tanaka N; Yamazaki T; Wakabayashi SI; Okumura T; Kobayashi H; Yamashita Y; Pydi SP; Nakajima T; Iwaya M; Sugiura A; Joshita S; Uehara T; Umemura T
Sci Rep; 2022 Nov; 12(1):18900. PubMed ID: 36344733
[TBL] [Abstract][Full Text] [Related]
4. Circulating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes.
Lee CH; Seto WK; Lui DT; Fong CH; Wan HY; Cheung CY; Chow WS; Woo YC; Yuen MF; Xu A; Lam KS
Diabetes Care; 2021 Sep; 44(9):2089-2097. PubMed ID: 34183428
[TBL] [Abstract][Full Text] [Related]
5. Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease.
Fujimori N; Umemura T; Kimura T; Tanaka N; Sugiura A; Yamazaki T; Joshita S; Komatsu M; Usami Y; Sano K; Igarashi K; Matsumoto A; Tanaka E
World J Gastroenterol; 2018 Mar; 24(11):1239-1249. PubMed ID: 29568204
[TBL] [Abstract][Full Text] [Related]
6. Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.
Di Mauro S; Scamporrino A; Petta S; Urbano F; Filippello A; Ragusa M; Di Martino MT; Scionti F; Grimaudo S; Pipitone RM; Privitera G; Di Pino A; Scicali R; Valenti L; Dongiovanni P; Fracanzani A; Rabuazzo AM; Craxì A; Purrello M; Purrello F; Piro S
Liver Int; 2019 Sep; 39(9):1742-1754. PubMed ID: 31169972
[TBL] [Abstract][Full Text] [Related]
7. Thrombospondin 2 is a key determinant of fibrogenesis in non-alcoholic fatty liver disease.
Kimura T; Iwadare T; Wakabayashi SI; Kuldeep S; Nakajima T; Yamazaki T; Aomura D; Zafar H; Iwaya M; Joshita S; Uehara T; Pydi SP; Tanaka N; Umemura T
Liver Int; 2024 Feb; 44(2):483-496. PubMed ID: 38010940
[TBL] [Abstract][Full Text] [Related]
8. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
9. Serum Thrombospondin-2 Levels Are Closely Associated With the Severity of Metabolic Syndrome and Metabolic Associated Fatty Liver Disease.
Wu X; Cheung CKY; Ye D; Chakrabarti S; Mahajan H; Yan S; Song E; Yang W; Lee CH; Lam KSL; Wang C; Xu A
J Clin Endocrinol Metab; 2022 Jul; 107(8):e3230-e3240. PubMed ID: 35532410
[TBL] [Abstract][Full Text] [Related]
10. Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease.
Mosca A; Comparcola D; Romito I; Mantovani A; Nobili V; Byrne CD; Alisi A; Targher G
Liver Int; 2019 Dec; 39(12):2317-2329. PubMed ID: 31436362
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort.
Polyzos SA; Slavakis A; Koumerkeridis G; Katsinelos P; Kountouras J
Horm Metab Res; 2019 Feb; 51(2):134-140. PubMed ID: 30273934
[TBL] [Abstract][Full Text] [Related]
12. Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
Mandelia C; Collyer E; Mansoor S; Lopez R; Lappe S; Nobili V; Alkhouri N
J Pediatr Gastroenterol Nutr; 2016 Aug; 63(2):181-7. PubMed ID: 26835904
[TBL] [Abstract][Full Text] [Related]
13. Serum ferritin levels predict histological severity in patients with nonalcoholic fatty liver disease in India.
Parikh P; Patel J; Ingle M; Sawant P
Indian J Gastroenterol; 2015 May; 34(3):200-8. PubMed ID: 26108652
[TBL] [Abstract][Full Text] [Related]
14. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
Alkhouri N; Johnson C; Adams L; Kitajima S; Tsuruno C; Colpitts TL; Hatcho K; Lawitz E; Lopez R; Feldstein AE
PLoS One; 2018; 13(8):e0202226. PubMed ID: 30161179
[TBL] [Abstract][Full Text] [Related]
15. FICK-3 Score Combining Fibrosis-4, Insulin Resistance and Cytokeratin-18 in Predicting Non-alcoholic Steatohepatitis in NAFLD Egyptian Patients.
Mohammed MA; Omar NM; Mohammed SA; Amin AM; Gad DF
Pak J Biol Sci; 2019 Jan; 22(10):457-466. PubMed ID: 31930835
[TBL] [Abstract][Full Text] [Related]
16. Utility of Multiparametric CT for Identification of High-Risk NAFLD.
Lubner MG; Graffy PM; Said A; Watson R; Zea R; Malecki KM; Pickhardt PJ
AJR Am J Roentgenol; 2021 Mar; 216(3):659-668. PubMed ID: 33474981
[No Abstract] [Full Text] [Related]
17. Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease.
Kakisaka K; Suzuki Y; Fujiwara Y; Abe T; Yonezawa M; Kuroda H; Ishida K; Sugai T; Takikawa Y
J Gastroenterol; 2018 Dec; 53(12):1285-1291. PubMed ID: 29680867
[TBL] [Abstract][Full Text] [Related]
18. Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis.
Loomba R; Jain A; Diehl AM; Guy CD; Portenier D; Sudan R; Singh S; Faulkner C; Richards L; Hester KD; Okada L; Li XJ; Mimms L; Abdelmalek MF
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1867-1876.e3. PubMed ID: 30448594
[TBL] [Abstract][Full Text] [Related]
19. The relationship and diagnostic efficacy of N-terminal propeptide type III collagen in pathological changes associated with non-alcoholic steatohepatitis.
Mi YJ; Zhang Z; Jin SL; Yan HM; Yang XM; Zhao J; Liu RX; Wu Y
Eur Rev Med Pharmacol Sci; 2024 Feb; 28(3):1052-1059. PubMed ID: 38375710
[TBL] [Abstract][Full Text] [Related]
20. Serum immunoreactive collagen IV detected by monoclonal antibodies as a marker of severe fibrosis in patients with non-alcoholic fatty liver disease.
Aida Y; Abe H; Tomita Y; Nagano T; Seki N; Sugita T; Itagaki M; Ishiguro H; Sutoh S; Aizawa Y
J Gastrointestin Liver Dis; 2015 Mar; 24(1):61-8. PubMed ID: 25822435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
